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ANGIOPLASTY-  STENTS AND ATHERECTOMY,  
LASERS AND OTHER DEVICES 
Long-Term Follow-Up of  "Stent*l ike" (_< 30% 
Diametar Stanosis Post) Ang iop las ty :A  Case for 
Provis ional  Stenting 
Patrick W. Sarruys, Aida J. Azar, Ulrich Sigwart, Woffgang Rutsch, Peter De 
Jaegere, Ferdinand Klemenij, Pim de Feyfor, Paul van den Heuvel, 
P~ma=-6 de Bmyne, Victor Legrsnd, Mario-ang~le Morel on behalf of the 
Benaste~ group. Thoraxcentre, University Hospital Dijkzigt, Rotterdam; 
The Netherlands 
Since it is uncl~3r whether the improved 1 yr clinical and 6 ruth angiogrephic 
out~ma after ste~ implantation is th~ result of its scaffolding properties or 
the late effect of a larger initial dilatation of the stenoals, we evaluated the 
outcome following 'Stent.like' PTCA (n = 90) and compared itto the complete 
Stunt grOup (n = 259) and the patients with a QCA diameter stenosis post- 
stantlng (DS) < 30=/0 (n = 213). The study paputation comprised 516 pts with 
stable angina reedomised toeither elective Palmaz-~chatz stent implantation 
or balloon angioplaety (PTCA) in Benestent-1. 'Stent-like' PTCA was defined 
as PTCA pts with DS _< 39%, 35% of pts in the PTCA group had a DS 
_< 30% compared to ~7% in the Stent. The results were as follows: event, 
dead/mi/cabg/pfoa; success, pts with assigned therapy and no inhospital 
events; re~tenoSis, >_ 50°/= diameter stsnosis follow-up (fup) 
"Stent-like" PTCA Total Stent population Stent DS _< 30% 
(n = 90) (n = 259) (n = 213) 
Success 78 (87%) 225 (87%) 199 (93=/=) 
Mid at fiJp (mm) 1.84 ~ 0.52 1.82 =1= 0.64 1.84 4- 0.61 
Restenosis 14 (16°/o) 51 (22%) ~ (18o/'=) 
Evem free 69 (77%) 199 (77=/°) 169 (79=/0) 
In conclusion: Our data suggest hat 'Stent-like' PTCA result in a clinical and 
angiographic long-term outcome equivalent o stentiog, therefore a strategy 
of provisional stenting shoutd be pmspaCtively tasted on a population treated 
with balloon angioplasty with on-line QGA DS __% 30°/o post procedure. 
~ A  RandOmized, Clinical o f  Radiation Therapy Trial 
to Reduce Restanosis Fol lowing Coronary 
Stenting---Early Results 
Paul S. Teirstein, Vincent MaSSullo, Shirish Jani, Robert J. Russo, Richard 
A, Schetz, Stephen Steuterman, Nancy B. Morris, Prabhakar Tripuraneni. 
Scripps Clinic, La Jolla, CA 
The SCRIPPS (Scripps Coronary Radiation to Inhibit Proliferation Post- 
Stunting) trial is a double-blind, randomized •al that couples coronary stent 
implantation with ionizing radiation to treat beth the recoil and proliferative 
components of restenosis. To date, following stent placement, 30 patients 
with restenotic lesions have been randomized to receive either transcatheter 
iridium-192 or placebo, non-radioaCtive seeds. Target vessels included na- 
tive o0ronades (13 lesions) and vein grafts (17 lesions). The mean lesion 
length was 10.2 + 6.3 mm and mean reference vessel diameter was 3.0 
± 0.7 ram. Dosimetry was calculated using intravascutar ultrasound (IVUS) 
measurements ot the radiation source to internal elastic membrane (IEM) 
distance. Iridium dbbons were advanced into the stented regfon through a 
non-centered, 4 Fr catheter, Mean iridium-192 specific activity was 97,6 :l= 
29.2 mCi and mean dwell time was 36 :i: 7.0 min. Mean shortest distance 
between radiation source and IEM was 1.02 d: 0.16 mm resuldog in a mean 
maximum target dose of 2651 -4- 349 cGy. The mean longest distance be- 
tween the radiation source and the IEM was 3.3 ± 0,47 mm resulting in a 
mean minimum radiation dose of 732 ± 83 cGy. 
All 10ts are scheduled for 6-rnonth angio and IVUS exam. Pts with subse- 
quent restenosis are decoded and, if in placebo arm, crossed over to radiation 
therapy. With a mean follow-up of 2,8 months, 2 pts (both in placebo group) 
required reinterVention for recurrent restenosis. No other adverse events 
have occurred. 
Radiation therapy coupled with stunting can be performed without early 
adverse events. Long-term results will be presented. 
~ Final Results of  Phases II, III, IV and V of  Medtronic 
Wiktor  Stent Implantation Without Coumadin 
Joseph Elias, Jean Pierre Monassier, Didier Carrie, Khalife Khalife, 
Gilles Grollier, Thierry Labbe, Michel Hanssen, Jean Marc Boulenc, 
Gerard Laval. CH Mulhouse, France 
From Desembei' 1993 to september 1995, in 5 French institutions, 422 
patients were prospectively treated attar Wiktor stent implantation with Ticlo- 
pidine (250 rag/day), Aspldn (100 mg/day) for 1 month and LMWH for 4 
weeks in phase II (79 patients), 2 weeks in phase Iti (96 patients), 1 week in 
phase IV (65 patients) and there was no LMWH in phase V (182 patients). 
Indications for stenting were: 
Phase II Phase ill Phase IV Phase V 
Suboptimal resu;1 56% 46% 40% 46% 
First intention 14% 26% 30% 38% 
Restenosis 18% 16O/o 2(R.~ 13% 
Bail OUt 12% 12% I(P/o 3% 
Must patients (92%) received 1 Stent, 6% recelvc~ 2 and 2'=/0 received 3. 
Results: 
Phase II Phase III Ph~Lse IV Phztse V 
Procedural success 97% 9~Y= ~ 3 -'/@ 97.5% 
Stent occlusion 1.36% 1% 1.5% 1% 
Death 1.36% 0% 0% 0% 
Emet0ency CABG 1.36% 1% 0% 0% 
Vx complications 1.36% 1% 1-5% 0% 
ConClusion: these data suggest that with a ~ Implantation technique, 
post Wiklor storing treatroent with Ticlopidine and Aspidn seems to reduce 
in Hospital major complications, additional treatment with LMWH does not 
seem beneficial. 
CARDIAC PACING 
~ FJectromagnetic Fi lters Impede Adverse 
interference o f  Pacemakers by Digital Cel lular 
Telephones 
Roger G. Card,o, Donald B. Williams, Ernest A. Tread, John S. Schor. 
Mount Sinai Medical Center, Miami Beach, FL 
Recent reports suggest that cr~jitat cellular telephones may adversely inter- 
fore with pacemaker function. The purpose of this study was to determine if 
electromagnetic filters in pacemakers impede interference from digital cellu- 
lar telephones. 
Sixty-fwe patients with permanent pacemakers from four different manu- 
facturers were studied (175 tests) D'mital cel!ular tel .ephnnes were nlacecl in 
dose proximity (1-5 crn) to the pulse generator during continuous electrocar- 
diographic monitoring. Adverse interference obselved included pacemaker 
inhibition, p-tracldog ol electromagnetic noise, asynchronous activation, and 
inappropriate safety pacing. Pacemakers from only one manufacturer had 
electromagnetic filter and these pacemakers were not susceptible to in- 
tederence (0% - 0/28). Units from the other three rnanufaclurers without 
electromagnetic filters were susceptible to intederence (16.9% - 11165; 41% 
-- 23Lr~6; and 46°/= - 12/26). Pacemakers from the manufacturer which were 
resistant to interference were furifrer tested in vibo. Standard units with 
electromagnetic filters were contpared with the same units which had the 
filtration device removed. Two pacemakers studied in vitro with etsctmreag- 
uetic tilters were completely resistant to interference when exposed to digital 
telephones (0% interference) while two unfiltered evices were susceptible 
to interference to the same digital telephones (100% interference). 
Conclusion: Electromagnetic filters in pacemakers can provide protection 
from interference from digital cellular telephones. 
~ Decreased Acute Current Drain With Steroid 
FJuting High Impedance Pacing Leads: Results 
From a Multicenter Clinical Tdal 
Kenneth A. Ellenbegen, Mark A. Wood, David M. Gflligan, Matt Zmijewsld, 
and Capsure Z Clinical Investigators. Medical College Of Virginia and 
McGuire VAMC, Richmond, VA 
Increasing pacemaker pulse generator longevity by redudng pacing current 
drain is a desired goal of advances in lead technology. The sensing and 
pacing performance of a new small l~p Steroid e~utJog electrode (1.2 mn~ 
surface area, high impedance lead, HI) Medtronic Capsure Z leads atrial 
J 5534 and vantrieular 5034 was compared to that of a standard steroid 
eluting lead (5.8 mm 2 sudace area, control lead, (3) Medlmnic CapSure SP 
leads atrial J 5524 and ventricular 5024. A total of 305 patients received 
pairs of the control ead ((3, 5524/5024) and 190 patients received pairs of 
the high impedance lead (HI, 5534/5034) and were studied with respect to 
pacing capture thresholds (CT) measured at 2.5 Volts in ms, lead impedance 
(ohms) and sensing threshold (S, mV). Clinical charscteristice of the patient 
population were similar. These leads are compared at 3 months tollowiog 
implantation below: 
i 
16A ABSTP~'~,CTS-Poster JACC Febnmry 1996 
CT (ms) I (~) Sensibly (mV) 
Atrium: HI-5534 0.06 4. 0.04 1049±190 ° 3.8~- 1.6 
Atrium: G-5524 0.06 4. 0.07 523 4- 239 3.5 4.1.B 
Ventricle: H1-5034 O.O7 :l: 0.1 1178:E252" 13.2:E4.7" 
Ventricle: G-5024 0.07 4. 0.1 613 4. 93 12.1 4. 4.5 
*p .,. 0.05. HI vs. C 
Thus, HI leads are associated with lower calculated current drain and 
higher impedance in both the atrium and ventrfcie, and higher S in the 
ventricle. These results may be of clinical significance in extending the 
longevity of pacemaker pulse generators. 
CARDIAC TRANSPLANTATION-  BAS IC  AND CL INICAL 
~ Intimel Thickening Develops Without Humeral 
Immunity in • Mouse Aort ic  AIIograft Model of  
Chronic Vascular Rejection 
Lawrence H, Chow, Susanna Huh, Jifu Jiang, Necdet Ozcay, Robert Zhong, 
J. Geoffrey Pickering. Roberts Research Institute and University of Western 
Ontado, London, Canada 
Antidonor antibodies have been asSociated with the development of intimal 
thi*..kening inhuman allogralt coronary arteries, however acausal relationship 
has not been established. To determine if humeral immune responses are 
necessary for the development of graft vascular disease, we performed 
abdominal aortic allngrafts (inframnal aorta; end-to-and anastomosis) from 
normal donor mica into [mmunodeficient SCID mice (no T or B cell function), 
and into "knockout" mice without B cell function due to a targeted deletion 
of the joining region (J H) gone segments for the Ig heavy chain. Isograft 
controls (no rejection) and allegraft controls, both in normal recipient mice, 
were also performed. Unlike hetemtopi¢ heart grafts, the mouse aortic grefts 
are functional, load-bearing, free of the influence of growth factors from 
intmventricular lhrombus formation, and unaffected by acute cellular ejection 
of the myocardium. 
Results: 1) At 8-10 weeks post-transplant, isograft contrnls had a normal 
aspeadng vessel wall, except for !ccetized intimal thickening at the suture 
lines. 2) Allcgreft controls showed concentric intimalthickening, extending the 
full length of the graft. A propo~on of the ir~timal cells was immunoreactive for 
Thy-1 (T cells), CD4, CD8, and Mac-1 (macrophages), respec~valy. 3) Ago- 
grafts in immunndeticiant SCID mice showed a virtual absence of neointimal 
formation, except at the suture lines. 4) Allogrefts in J H-deteted mice without 
humeral immunity showed marked intimal thickening, indistinguishable from 
that of normal (immunocompetent) recipients. 
Conclusion: AIIograft intimal thickening is due to an allogsnaic immune 
response of the recipient, and is independent of the influence of humeral 
effector mechanisms. 
~ Capil lary Deposition of  C4d Complement 
Fragment: A New DtegnoMic Tool for  Humoral 
Rejection In Heart Transplant Recipients 
Thomas M. Behr, Klaus Richter, Petra Fischer, Chdstoph H. Spas, 
Bruno Meiser, Dieter Pongratz, Helmut Feucht, Kad Thalsen, Chdstiane 
E. Angermann. University of Munich, Germany 
Histological and immunohistological diagnosis of humeral rejection (HR) 
remains controversial. The classical pathway C1 q and C3c complement split 
products as well as IgG and IgM have been studied as markers of HR; 
however, their diagnostic value appears limited due to lack of specificity and 
their short endothelial adhesion time, C4d has been successfully used as an 
indicator of HR in human kidneys, but was never studied in Cardiac allografts. 
C4d Is covalantiy bound to the endothalium (disultid bddge); due to longer 
persistence, it should thus indicate HR more reliably in endomyocardial 
biopsies (EMB). To test this hypothesis, 16 patients were monitored with 
conventional histology (CH) & immunohietology(IH) for the first 3 months 
post cardiao transplantation (n = 38 satisfactory EMB), All patients received 
triple drug therapy including either FKS06 (n = 11) or cyciosporine A (n = 
5). With IH, the presence of C4d was compemd with Clq, C3c, IgG and 
IgM, Results: In none of the EMB, CH identified acute cellular rejection > IB 
(ISHL'r); laR was not suspected by CH in any of the EMB. 
EMB loG/M+ Glq+ C3c+ patientS morlaltty. 
C4d++ 9 6 3 5 6 50% (3)* 
C4d+l- 10119 16 2 9 10 0%* 
• Fisher exact p = P..036 
Patie~,';,, who died (1 graft failure, 2 sudden deaths within < 10 days of 
C4d++ EMB), had the most extensive deposition of C4d. These preliminary 
results suggest that extensive vascular deposition of CAd may be a new and 
more specific diagnostic marker for clinically significant HR. Patients with 
CAd++ seem to be at a high dsk to die shortly from either graft failure or 
sudden death. 
~ Impact of  Prophylact ic  Immediate Post-Transplant 
Ganciclovir on Development of Transplant 
Atherosclerosla: A Randomized 
Placebo-Control led Study 
Hannah A. Valentine, Shao-zhou Gas, Santosh Gopinathan, Dale 
G. Ranlund, Sharon A. Hunt, Thomas C, Medgan, Phi!!p _r"~,er, Edward 
B. Stinson, John S. Schroecier. Stanford University, Stanford, CA 
We have previously identified CMV disease as a significant predictor of trans- 
plant coronary disease ('rxCAD) and have reported a protective effect of dil- 
tiazem, We hypothesized that TxCAD is prevented by prophylactic treatment 
with ganciclovir, based on our controlled trial in which it Inhibited CMV dis- 
ease dudng the first 6 months alter heart ransplantation. Methods:The study 
population included 143 consecutive patients (125 men, 18 women aged 43 
± 13 years), d0uble-blinded and randomized to receive either ganciclovir 
or placebo during the initial 28 days after transplantation. Immunosuppres. 
sion consisted of OKT-3 prophylaxis and maintenance with ¢yclosperine (3- 
6 mg/kg/d), prednisane (0.1--1 mg/kg/d), and azathiopdne (2-4 mg/kg/d). 
Mean follow-up time was 3.7 4. 1.3 years. Using MantsI-Heonszet analysis 
we compared the actuarial incidence of TxGAD, defined by angiagraphy as 
the presence of any stenosis irrespective of severity, in patients stratified 
according to the use of calcium channel blockers. To determine whether 
ganciclovir use had an independent protective ffect against TxCAD, Cox re- 
gression analysis was performed, including donor age, calcium blocker use, 
and rejection episodes in) as potentially confounding co-vadatss. Results: 
TxCAD evaluation was unavailable in 23 patients due to early death or limited 
follow-up. 
Probability of Freedom From TxCAD (%) at 5 years 
DHPG No DHPG 
N % d~sease-free N % disease-free 
No Ca blower In = 54) 29 614.11 25 33:1:15 0.03 
Ca blocker (n = 66) 33 504.14 33 49"4-13 N.S 
By Cox regression analysis the only independent predictors of TxCAD were 
donor age > 40 years (relative risk = 2.7, confidence intervals = 1.3--5.7, p 
= 0.03), and no DHPG prophylaxis 0elative risk = 2.1, confidence intervals = 
1,1--4,1, p = 0.03). 
Conclusion: These data suggest hat ganciclovir protects against TxCAD in 
patients not treated with calcium blockers. Further studies in a larger sample 
are needed to determine the mechanism whereby ganciclovir influences the 
process of transplant atherosctsrosis. 
CARDIOPULMONARY RESUSCITAT ION/EMERGENCY 
CARDIAC CARE 
~ Expression of  the AT1 Receptor in the Heart  
Fol lowing Myocardia l  Infarction (MI) 
Barry Gmenberg, Jay Ambrose, David Pribnow, Kalth Perkins, 
Jean-Made Gasc, Oregon Health Sciences Universi~ Portland, OR; 
University of California, San Diego, CA 
Angictanain (A)it is believed tO play an important role in post-MI remodeling. 
All effects are mediated predomlnately through an interaction with Type I 
(AT1) receptors. To determine if expression of the AT1 receptor is altered 
post-MI and to localize changes within the heart, we assessed left ventricles 
(LV) of male Spregue-Dawley rats 5 days post left anterior descending coro- 
nary artery ligalion or sham operation. MI rats were either untreated (n = 6) or 
received 25 mg/kg/day enalapfil (n = 4), AT1 mRNA was quantitated by RT* 
PCR amplicatlon using an altered ATt cRNA as internal control. At a constant 
input RNA, the AT~ mRNA was increased from 0.11 ± 0.02 (mean :E SE) in 
controls (n = 5) to 1.47 4- 0.52 in post-MI rats (p < 0.05). In enalapdl treated 
MI rats the value was reduced to 0.55 4- 0.22 (13 = NS vs controls), Emul- 
sion autoradiography using z~l-Ait demonstrated increased AT1 receptor 
density which was localized to the peri-infaretion region. In situ hybddizution 
with an AT~ specific riboprobe confirmed this distribution. Non-myocyte cells 
with the appearance of fibroblasts appeared to be involved, These findings 
demonstrate that expression of the AT1 receptor is enhanced post MI and 
that the changes appear to involve cardiac fibmblaets in the pad-infarction 
region rather than cardiac myocytes. Since increased AT~ expression would 
augment RAS effects on cardiac remedeflng the attenuation with enalapril 
could explain some of the benefits of ACE Inhlbitors in this setting. 
